Skip to content
Menu

Atossa Therapeutics, Inc. ATOS

Full chart Compare
Set alert

Price alert · ATOS

All alert types
1.93 USD -0.03 (-1.53%)

Regular-session close

1.93 0.00 0.00%

After hours · Nov 16, 4:00 PM ET

1.86 Day range 2.09
1.70 52-week range 14.85
YTD
-78.19%
1 year
-83.92%
Market cap
19.26M
EPS (ttm)
-4.00
Shares out
125.80M
Forward P/E
-3.81
YTD return
-78.19%
1-year return
-83.92%
50-day average
1.31
200-day average
1.39
Enterprise value
46.47M
Volume
69.55K
Avg volume
70.74K
Open
1.98
Previous close
1.96
Day's range
1.86 – 2.09
52-week range
1.70 – 14.85
Beta
1.23
Analysts
Strong Buy
Price target
6.00 (+210.9%)

5D -0.26 (-11.82%)

22.20TueWedThuFriMon1.94

Key statistics

Price / book
1.76
Free cash flow
-12.76M
Total cash
74.77M
Return on equity
-31.30%
Short % of float
9.23%

Fundamental scorecard

6 of 25 checks passed on ATOS’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ATOS Revenue — quarterly 0
ATOS Net income — quarterly -5.64M
ATOS EPS — quarterly -0.56

Earnings

ATOS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.06-0.05+0.01+16.67%
Aug 12, 2024Jun 1, 2024-0.05-0.050.000.00%
May 13, 2024Mar 1, 2024-0.07-0.05+0.02+28.57%
Apr 1, 2024Dec 1, 2023-0.05-0.06-0.01-20.00%
Nov 13, 2023Sep 1, 20230.00-0.05——
Aug 14, 2023Jun 1, 20230.00-0.06——

Upgrades / downgrades

ATOS analyst upgrades and downgrades
DateFirmActionFromTo
Dec 13, 2024HC Wainwright & Co.reitBuyBuy
Dec 12, 2024HC Wainwright & Co.reitBuyBuy
Dec 9, 2024Ascendiant CapitalmainBuyBuy
Nov 13, 2024HC Wainwright & Co.mainBuyBuy
Nov 5, 2024HC Wainwright & Co.reitBuyBuy
Oct 31, 2024HC Wainwright & Co.reitBuyBuy

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ATOS — it syncs with the Stock Master app.

Insider holders

ATOS insider holders
InsiderRelationLatest transactionDateShares held
FINN JONATHAN F.DirectorPurchaseApr 9, 202425,000
WEAVER GREGORY LOfficer and DirectorSaleNov 14, 202355

Institution ownership

ATOS institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.68%9,667,6159.96MSep 29, 2024
Vanguard Group Inc5.25%6,598,2966.80MSep 29, 2024
Geode Capital Management, LLC2.24%2,814,4462.90MSep 29, 2024
State Street Corporation1.38%1,732,2211.78MSep 29, 2024
Renaissance Technologies, LLC1.04%1,310,0701.35MSep 29, 2024
Northern Trust Corporation0.76%954,199982.82KSep 29, 2024

Fund ownership

ATOS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund3.13%3,939,4414.06MSep 29, 2024
iShares Russell 2000 ETF2.60%3,268,2683.37MOct 30, 2024
Vanguard Extended Market Index Fund1.33%1,667,7481.72MSep 29, 2024
Fidelity Small Cap Index Fund1.04%1,304,1951.34MAug 30, 2024
iShares Russell 2000 Value ETF0.85%1,065,2271.10MOct 30, 2024
Fidelity Extended Market Index Fund0.54%676,434696.73KOct 30, 2024